Researchers started a retrospective study to explore the association between psoriasis and chronic kidney diseases (CKD). They conducted a population-based cross-sectional study using data from the National Health and Nutrition Examination Survey (NHANES). Logistic regression analyses revealed the potential association between psoriasis and CKD risk. Furthermore, causality was evaluated through a Mendelian randomisation analysis using large-scale genome-wide association studies of psoriasis and CKD. The primary method used was the Inverse variance-weighted (IVW) analysis.
The results showed that of 16,750 participants, 39 out of 429 patients with psoriasis had CKD (9.1%), while the same percentage (9.1%) was observed in 1481 of 16,321 participants without psoriasis. In the fully adjusted model, there was no observed association between psoriasis and CKD (OR: 0.77, 95%CI: 0.53–1.10). For the MR analysis, 36 single-nucleotide polymorphisms (SNPs) were chosen as instrumental variables. The IVW analysis indicated a genetically predicted psoriasis association with a high risk of CKD (OR: 1.025, 95%CI: 1.001–1.049). Even after eliminating 2 SNPs linked to heterogeneity, the association persisted (OR: 1.028, 95%CI: 1.006–1.050).
Investigators concluded that genetically predicted psoriasis was associated with a higher risk of CKD, suggesting a potential causal relationship.
Reference: Yin S, et al. Nephrology 2023;28(11):611-619.
Originally Published By Physician’s Weekly. Reused by Medicom Medical Publishers with permission.
©2023 Physician’s Weekly. All rights reserved. No works may be reproduced without expressed written consent from Physician’s Weekly. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by Physician’s Weekly.
Posted on
Previous Article
« Strategies for Early Psoriatic Arthritis Recognition in Psoriasis Patients: GRAPPA Survey Findings Next Article
A systematic review of interventions to improve AET adherence in breast cancer survivors »
« Strategies for Early Psoriatic Arthritis Recognition in Psoriasis Patients: GRAPPA Survey Findings Next Article
A systematic review of interventions to improve AET adherence in breast cancer survivors »
Related Articles
August 26, 2019
Novel selective IL-23 blocker highly effective over 2 years
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com